1 EXHIBIT 11 DURAMED PHARMACEUTICALS, INC. AND SUBSIDIARIES Statement Regarding Computation of Earnings Per Share Three months ended Six months ended June 30, June 30, 1997 1996 1997 1996 ------------ ------------ ------------ ------------ Primary: Weighted average common shares outstanding 14,786,221 10,122,713 14,715,272 9,344,296 Assumed conversion of preferred shares to common shares * * * * Net effect of dilutive stock options and warrants - based on treasury stock method using the average market price * * * * ------------ ------------ ------------ ------------ Totals 14,786,221 10,122,713 14,715,272 9,344,296 ============ ============ ============ ============ Net loss $ (3,495,085) $ (1,875,736) $(10,253,447) $ (4,311,749) ============ ============ ============ ============ Per share amount $ (0.24) $ (0.19) $ (0.70) $ (0.46) ============ ============ ============ ============ Fully diluted: Weighted average common shares outstanding 14,786,221 10,122,713 14,715,272 9,344,296 Assumed conversion of preferred shares to common shares * * * * Net effect of dilutive stock options - based on treasury stock method using the year-end market price, if higher than average market price * * * * ------------ ------------ ------------ ------------ Totals 14,786,221 10,122,713 14,715,272 9,344,296 ============ ============ ============ ============ Net loss $ (3,495,085) $ (1,875,736) $(10,253,447) $ (4,311,749) ============ ============ ============ ============ Per share amount $ (0.24) $ (0.19) $ (0.70) $ (0.46) ============ ============ ============ ============ *Conversion of stock options and preferred shares are not assumed in the computations because their effect is antidilutive.